TABLE 2. Probe Sets Identified by Both Time-Dependent and Time-Independent Methods

Supplementary Table 1. Probe Sets Selected by WRRAS. 33 of the 6293 Probe Sets Passing the Data Filter for Which Expression Levels were Significantly (p 0.005) Associated with Time to Brain Tumor

Supplementary Table 2.  70 Probe Sets Distinguished Patients Who Did Versus Did Not Develop Secondary Brain Tumors (Selected by Linear Discriminant Analysis)a

Table 1. List of 254 genes used at least once in the 30 leave-one-out cross-validation loops

TABLE II. Top 10 up- or down-regulated genes identified in each of the comparisons shown in Table 1A

Supplementary Data Table 1S/ List of genes that were differentially expressed during the partial hepatectomy time course with an absolute fold change of 1.5 or higher  as identified by PaGE analysis (as shown in Figure 1B)

Table 3. Selected Genes Whose Expression Is Downregulated in Mouse Bladder Tumors Compared with Normal Bladder Epithelia Identified by Microarray.

Table 2. Selected Genes Whose Expression Is Upregulated in Mouse Bladder Tumors Compared with Normal Bladder Epithelia Identified by Microarray.

Table 3. Differentially Expressed Genes in Microdissected PDAC and Microdissected Normal Ductal Cells Using High-Density Microarrays.

Table 2. Gene expression was analyzed in five pairs of 5-fluorouracil (5-FU) resistant and parental cancer cell lines on DNA microarrays. Signature of 5-FU sensitivity predictive gene set identified in unsupervised analysis

Table 3. Gene expression was analyzed in five pairs of 5-fluorouracil (5-FU) resistant and parental cancer cell lines on DNA microarrays. Signature of 5-FU resistance associated genes identified in supervised analysis

Table 1 Summary of genes up-regulated in EFTs compared with normal body atlas

Table 2. BMP signaling molecules affected by BMP-6 in prostate cancer

Table 3b. Cell cycle and Id proteins down-regulated by BMP-6

Table 3a. Cell cycle and Id proteins up-regulated by BMP-6

Figure 3b. Average expression of each gene in the CD19+ and CD19? subpopulations isolated from the tumor-biopsy specimens for immune response 2